BlitzLab Scoring · Oct 2026 · Model v1.0 (frozen)
HubSpot — Blitz Index 62 (B)
PLG distribution and multi-hub lock-in are real, but decelerating growth and an unquantified AI curve stop it 3 points short of the line.
62Grade B
Confidence: High · Category: platforms
Score breakdown
| Section | Score | Detail |
|---|---|---|
| A · Speed | 15 / 25 | 1H 2026 growth +21.5% with guidance reaffirmed — but the trajectory decelerates (33% → 19%); NRR 103.5% is the weak gear |
| B · Moat | 38 / 60 | Multi-hub lock-in: 70% of installed ARR sits on 3+ products; PLG distribution — Breeze AI revenue still undisclosed |
| C · Creative destruction | 9 / 15 | Killing its own seat-based model with agentic pricing — self-destruction announced, not yet visible in revenue |
| D · BlitzFailing | 0 | No debt, single share class, buybacks shrink the share count — a zero-demerit file |
Radar axes (0–100): Moat 63.3 · Speed 60 · Creative 60.
Watch item
Gates: G1 ✓ · G2 ✓ (estimate — the company discloses no quantified TAM). Bar ≈ $34.5B (TTM revenue × 10) vs a ~$100B+ core CRM market.
Strengths
- 1H 2026 +21.5% — 20%-range growth held inside a decelerating trajectory; FY2026 guidance (+18%) reaffirmed Oct 1
- Multi-hub proof: customers on 3+ hubs are 70% of installed ARR; $120K+ ARR deals +38% YoY
- Gross margin 83.8% and first GAAP profit (+$7.4M FY2025, $43.3M in Q2 2026); non-GAAP FCF $594.9M
- Zero convertibles and buybacks cut the share count 5.5% in six months — dilution more than offset
Concerns
- Deceleration: 33% → 25% → 21% → 19%, with Q3 2026 guidance at +14% — low-teens growth is next year's risk
- NRR 103.5% (new formula; ~102% in Q2 2026) — a weak expansion engine next to low-120s platform peers
- Breeze AI revenue is nowhere quantified — the AI transition cannot yet be verified in numbers
- The ~7% restructuring (Oct 1) reads both as AI leverage and as cost defense against slower growth
Next earnings
Nov 4, 2026 · Expected
Coverage
HubSpot, Inc. · Q3 2026 due Nov 4, 2026 (expected) · Score 62 · Grade B
BlitzLab scores businesses against a scholar’s standard — not investment advice. No price targets, no buy/sell recommendations. Figures are from SEC filings (XBRL) as labeled in the source scorecard.